Ireland· IE-PA-EU/1/24/1883/001-002
AUGTYRO 40 mg hard capsules
A repotrectinib product containing repotrectinib, registered in Ireland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 10 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Repotrectinib is registered in 10 of 19 countries.
Countries holding a registration under ATC L01EX28 (repotrectinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Repotrectinib · ATC L01EX28
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Repotrectinib
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Ireland (IE)
- ATC code
- L01EX28
- ATC class
- Repotrectinib
- Defined daily dose
- 0.32 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1883/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Repotrectinib in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAUGTYRO
- United StatesAugtyroE.R. Squibb & Sons, L.L.C.
- IcelandAugtyroBristol-Myers Squibb Pharma EEIG
- BelgiumAugtyro 40 mgBristol-Myers Squibb Pharma
- NorwayAugtyroBristol-Myers Squibb Pharma EEIG
- PolandAugtyroBristol-Myers Squibb Pharma EEIG
- SwedenAugtyro 40 mg Kapsel, hårdBristol-Myers Squibb Pharma EEIG
- NetherlandsAUGTYRO 40 mg harde capsulesBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Augtyro
- Liechtenstein · Augtyro
- Norway · Augtyro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dee0d0cf-63fe-4997-9436-4cd260d4af6b GET /v1/drugs/dee0d0cf-63fe-4997-9436-4cd260d4af6b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EX28"
],
"strength": null,
"pa_number": "EU/1/24/1883/001-002",
"substances": [
"Repotrectinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "13/01/2025",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about repotrectinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.